Twist Bioscience (TWST) Q3 2026 earnings review
Top-Line Acceleration Drives the Final Push to Breakeven
Twist Bioscience delivered a decisive beat-and-raise quarter, marking its 14th consecutive period of sequential revenue growth. Driven by an AI-fueled 39% YoY surge in the DNA Synthesis and Protein Solutions (DSPS) segment, total revenue accelerated 23% to $118.4M. Gross margins recovered sequentially to 52.8%, offsetting concerns from a dip in Q2. However, the cost of this growth remains high: SG&A expenses ballooned 27% YoY, causing the YoY operating loss to widen. Despite this, sequential Adjusted EBITDA improved, and management firmly reiterated the holy grail of their multi-year narrative: Adjusted EBITDA breakeven in Q4.
🐂 Bull Case
14 consecutive quarters of sequential top-line growth is rare. The platform's scale is capturing massive AI drug discovery demand, pushing FY26 guidance up by $12M at the midpoint.
After a deliberate investment phase suppressed Q2 gross margins to 51.6%, Q3 rebounded to 52.8%. Operating leverage is kicking in just in time for the Q4 profitability target.
🐻 Bear Case
SG&A expenses grew 27% YoY (from $63.4M to $80.7M), faster than the 23% revenue growth. This resulted in a widened operating loss of $36.3M versus $30.1M a year ago.
Cash and short-term investments have dwindled from $232M at the end of FY25 to $167M. Achieving and sustaining the Q4 breakeven target is no longer a luxury; it is a balance sheet necessity.
⚖️ Verdict: 🟢
Bullish. The underlying demand in the DSPS segment is explosive, and the company is consistently beating its own top-line metrics. If they hit the Q4 breakeven target, the stock's narrative shifts entirely from cash-burn risk to compounding profitable growth.
Key Themes
DSPS is Accelerating on AI Tailwinds
The DNA Synthesis and Protein Solutions (DSPS) segment is Twist's undisputed growth engine. Growth is Accelerating: jumping from 27% YoY in 26Q1, to 28% in 26Q2, and now a massive 39% in 26Q3, reaching $56.6M. The relentless demand from AI-enabled drug discovery—which requires thousands of complex sequences to train models—has transformed this segment from a steady grower to a breakout star.
NGS Segment Steadies the Ship
The NGS Applications segment demonstrated Stable momentum, growing 12% YoY to $61.8M (up 8% sequentially from $57.4M). Having navigated through a major customer transition earlier in the fiscal year, this segment provides a highly predictable, recurring revenue baseline built on diagnostics and Minimal Residual Disease (MRD) applications.
SG&A Bloat Diluting Operational Leverage
Management frequently cites a 75-80% incremental gross margin drop-through, but it is currently being absorbed by heavy middle-of-the-P&L spending. SG&A expenses surged to $80.7M in Q3, up 27% YoY. Because this outpaced the 23% revenue growth, the GAAP operating loss actually widened by $6M YoY. The narrative of 'disciplined execution' requires a sharp deceleration in SG&A growth moving into FY27.
Broadening Addressable Markets via Innovation
Twist officially launched 'Twist Complex Genes' out of its early access phase. This moves the company closer to its goal of accepting 99.9% of sequence designs. In an industry where a single unmanufacturable sequence can cause a customer to route an entire multi-million dollar AI-discovery order to a competitor, this technical expansion is a critical defensive moat and market share driver.
Other KPIs
Reversing the dip seen in Q2 (51.6%), gross margin improved 120 basis points sequentially. The return to the mid-52% range confirms that the prior quarter's margin compression was indeed tied to transient capacity investments rather than structural pricing degradation.
Net Loss dramatically reversed from a $20.4M profit a year ago—but context is essential. Q3 FY25 included a one-time $48.8M gain from the Atlas Data Storage spinout. Adjusting for this noise and stock-based compensation, Adjusted EBITDA of -$11.3M is actually a sequential improvement from Q2's -$13.3M, keeping the Q4 breakeven dream alive.
Accelerating volume growth. Shipped 369,000 genes this quarter, up a staggering 55% YoY compared to 237,000 in the same period last year. This highlights massive platform utilization and confirms management's narrative of gaining market share in a constrained funding environment.
Guidance
Accelerating. Raised by $12 million at the midpoint. This implies approximately 21% YoY growth, effectively locking in an exceptional year of execution in a tough biotech macro environment.
Accelerating. Guidance implies ~25% YoY growth in the fourth quarter, with expected sequential increases across both DSPS and NGS segments. This indicates no signs of demand fatigue.
Reversing. Management reiterated the pledge to hit Adjusted EBITDA breakeven in Q4. Moving from a -$11.3M loss in Q3 to $0 in a single quarter requires immense discipline; the company is betting on the $123M+ revenue scale to naturally pull them across the line.
Key Questions
SG&A Trajectory Post-Breakeven
SG&A grew 27% YoY in Q3, outpacing revenue growth. As you cross the Adjusted EBITDA breakeven threshold in Q4, how should we model operating expense growth in FY27? Will you allow margin expansion to flow to the bottom line, or immediately reinvest it?
Durability of AI Discovery Surge
DSPS accelerated to 39% YoY growth, heavily driven by AI model training. Are these customers shifting from initial burst 'model building' phases into predictable, recurring 'production' phases, and what is the typical re-order rate for these accounts?
Complex Genes Revenue Impact
With the commercial launch of Twist Complex Genes, what percentage of historically rejected orders do you expect to recapture, and how does the margin profile of these highly complex sequences compare to your standard clonal genes?